Literature DB >> 1184942

Clinico-pathological studies on naturally-occurring bovine fascioliasis in the Sudan.

E M Haroun, M F Hussein.   

Abstract

An investigation was made of the pathological, haematological and biochemical aspects of naturally-occurring bovine fascioliasis in the Sudan. 228 animals infected with Fasciola gigantica and 25 non-infected controls were used in the study. The infected cattle revealed emaciation, typical liver pathology, and, occasionally, lesions in the lung and the pancreas. Analysis of their sera also showed reduced albumin values, increased globulin concentrations and decrease albumin/globulin ratio, in addition to increased arginase activity. The serum iron concentration, on the other hand, was decreased, while the total iron binding capacity increased and the resultant iron saturation values reduced. Haematological findings in the infected animals included reduced erythrocyte counts, decreased haematocrit values, increased mean corpuscular volumes, eosinophilia and decreased neutrophil, lymphocyte and monocyte counts. Other parameters were similar in infected and control cattle.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1184942     DOI: 10.1017/s0022149x00023567

Source DB:  PubMed          Journal:  J Helminthol        ISSN: 0022-149X            Impact factor:   2.170


  3 in total

1.  Comparison of production losses caused by chronic Fasciola gigantica infection in yearling Friesian and Boran cattle.

Authors:  L W Wamae; J A Hammond; L J Harrison; J A Onyango-Abuje
Journal:  Trop Anim Health Prod       Date:  1998-02       Impact factor: 1.559

2.  A commercial preparation of catalase inhibits nitric oxide production by activated murine macrophages: role of arginase.

Authors:  Y Tian; Y Xing; R Magliozzo; K Yu; B R Bloom; J Chan
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

3.  Economic importance of bovine fascioliasis in Nigeria.

Authors:  A Ogurinade; B I Ogunrinade
Journal:  Trop Anim Health Prod       Date:  1980-08       Impact factor: 1.559

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.